Local action of sodium alendronate in bone repair of spontaneously hypertensive rat (SHR).
BACKGROUND
The arterial hypertension is a disorder characterized by relevant alterations in the bone tissue. The sodium alendronate is indicated in the treatment of bone diseases, because of its affinity with the hydroxyapatite, inhibiting the bone reabsorptions.


OBJECTIVE
To analyze local action of the sodium alendronate in the bone repair of spontaneously hypertensive rat (SHR).


METHODS
A bone defect was created in the left femur of 80 rat. In agreement with the material used at the place, four groups were created: control (C), starch (St), alendronate 1 mol (A1) and alendronate 2 mol (A2). After 7 and 21 days, the animals were sacrificed. Histomorfometrical and histological analyses were accomplished and the data were submitted the variance analysis (ANOVA) and test of Tukey (5%).


RESULTS
At 7 days, in the area of the defect, conjunctive tissue with hemorrhage and inflammation in all of the groups was observed. Some presented osteoid matrix. The groups A1 and A2 presented, further, a fibrin net. At 21 days, the bone trabeculae practically closed the extension of the defect in the groups C and St. In the group A1 of male animals, trabeculae were observed that irradiated from the medullary canal to the area of the defect. In the groups A1 and A2, only presence of conjunctive fabric with low osteoid deposit was observed. An outstanding histological discovery was the formation of extracortical subperiosteal bone tissue in animals of the groups A1 and A2.


CONCLUSIONS
The administration of sodium alendronate did not contribute to bone repair in SHR rat, but possibly has been responsible for the extracortical bone formation observed.
Nobre
Mônica Dal Pian
MD
Universidade Estadual Paulista Júlio de Mesquita Filho - São José dos Campos, Pindamonhangaba, Araraquara, SP - Brazil. modalpian@gmail.com
Fernandes
Raquel Guedes
RG
Chin
Chung Man
CM
Faig-Leite
Horácio
H
D019386:Alendronate / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D004195:Disease Models, Animal; D005260:Female; D005264:Femoral Fractures / Q000188:drug therapy; D005269:Femur / Q000187:drug effects / Q000293:injuries; D006973:Hypertension / Q000150:complications*; D008297:Male; D051381:Rats; D011918:Rats, Inbred SHR; D013997:Time Factors
D050071:Bone Density Conservation Agents; D019386:Alendronate